Skip to content

Blog

Tag: Vectors

<a href="https://www.bioagilytix.com/blog/category/gene-therapy/">Gene Therapy</a>

Impact of Pre-Existing Immunogenicity Against AAV on Gene Therapy Trials

  • July 23, 2020

The concept of using pre-existing immunogenicity as an exclusion criteria for gene therapy clinical trials is changing. BioAgilytix’s Chief Scientific Officer, Dr. Jim McNally, explores…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/gene-therapy/">Gene Therapy</a>

Gene Therapy Trends: Conditional Approval of Zynteglo Brings Ex Vivo Gene Therapy Into Focus

  • August 21, 2019

The recent approval of Zynteglo further builds credibility to the specific and emerging class of cell therapies engineered via “ex vivo” gene therapy. We explain…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/gene-therapy/">Gene Therapy</a>

Immunogenicity Assessment of Gene Therapy Compounds

  • May 10, 2019

By Dr. Arno Kromminga and Dr. Lydia Michaut

Gene therapy has experienced an exciting resurgence in the post-genomic era, but unwanted immunogenicity is still a…

Find Out More